CervoMed Ends $20 Million Stock Sales Agreement with BTIG
Company Announcements

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

The latest update is out from CervoMed ( (CRVO) ).

CervoMed Inc. had an agreement in place to sell up to $20 million of its common stock through BTIG, LLC, under a Sales Agreement that allowed for “at-the-market” offerings. However, the company decided to terminate this agreement without incurring any penalties or selling any shares under this arrangement. The termination will take effect on October 11, 2024.

For detailed information about CRVO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCervoMed to Present Phase 2b Trial Results
TheFlyCervoMed to present at International Lewy Body Dementia Conference
TheFlyCervoMed reports last patient last visit in Phase 2b RewinD-LB trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App